Skip to main content
logo
Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · Real-Time Price · USD
0.6915
-0.0335 (-4.62%)
Sep 1, 2026, 4:00 PM EDT - Market closed

Estrella Immunopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Jun '24 Jun '23 Jun '22
Selling, General & Admin
2.72.812.443.20.660.3
Research & Development
6.9810.256.414.1110.451.39
Operating Expenses
9.6813.068.857.3111.111.69
Operating Income
-9.68-13.06-8.85-7.31-11.11-1.69
Pretax Income
-10.01-13.06-8.85-7.31-11.11-1.69
Income Tax Expense
-0000--
Net Income
-10.01-13.06-8.85-7.31-11.11-1.69
Preferred Dividends & Other Adjustments
------0.61
Net Income to Common
-10.01-13.06-8.85-7.31-11.11-1.07
Net Income Growth
------
Shares Outstanding (Basic)
403736270-
Shares Outstanding (Diluted)
403736270-
Shares Change
10.44%1.63%33.68%8764.81%--
EPS (Basic)
-0.25-0.35-0.24-0.27-36.35-
EPS (Diluted)
-0.25-0.35-0.24-0.27-36.35-
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Jun '24 Jun '23 Jun '22
EBIT
-9.68-13.06-8.85-7.31-11.11-1.69
SEC Filings: 10-K · 10-Q